drugset / Trial / NCT01216267
Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The goal of this study is to compare several methods for measurement of Chromogranin A in their ability to serve as a marker for disease activity in patients with neuroendocrine tumors. Further, in a subgroup, we will determine if taking a proton pump inhibitor affects Chromogranin A levels.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | — |